FDA Updates Sotrovimab Emergency Use Authorization

The Centers for Disease Control and Prevention (CDC) Nowcast data from April 5, 2022,  estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50% in all Health and Human Services (HHS) U.S. regions. Data included in the health care provider fact sheet show the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant. Due to these data, sotrovimab is not authorized in any U.S. state or territory at this time. 

New Paxlovid Dose Pack Author​ized by FDA

On April 14, 2022, the FDA revised the Emergency Use Authorization (EUA) for the COVID-19 oral antiviral therapeutic Paxlovid to authorize an additional dose pack presentation with appropriate dosing for patients with moderate renal impairment within the scope of the EUA. As a result, Paxlovid will soon be available in two package presentations. 

NIH Resource: Study Looks for Long COVID Risk Factors 

In a study supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Center for Advancing Translational Sciences, and the National Institute on Drug Abuse, researchers enrolled 209 people ages 18 to 89 who had laboratory-confirmed SARS-CoV-2 infections. 

Post-ICU COVID-19 Clinics

Post-ICU COVID-19 clinics are newly established programs providing care for patients with post-intensive care syndrome (PICS) related to COVID-19. During this webcast, subject matter experts discussed how post-ICU COVID-19 clinics developed with an interdisciplinary model improve outcomes and support patients, family members, and transitions of care.

Characteristics of Post-ICU and Post-COVID Recovery Clinics in 29 U.S. Health Systems

From Critical Care Explorations The authors describe the structure and process characteristics of existing and newly implemented ICU-RCs and COVID-RCs in a subset of large health systems in the United States.

Increasing Mortality in Venovenous Extracorporeal Membrane Oxygenation for COVID-19–Associated Acute Respiratory Distress Syndrome

From Critical Care Explorations The authors determine the factors associated with mortality in venovenous extracorporeal membrane oxygenation (V-V ECMO) patients with COVID-19 infection and provide an updated report of clinical outcomes for patients treated with V-V ECMO for COVID-19 in Minnesota.

Albumin Kinetics in Sepsis and COVID-19

From Critical Care Explorations In this Letter to the Editor the authors concluded that the pattern of albumin kinetics may be predictive of outcome in COVID-19 and sepsis-induced ARDS.

The Third Wave: Comparing Seasonal Trends in COVID-19 Patient Data at a Large Hospital System in New York City

From Critical Care Explorations The authors compare the demographics and outcomes of hospitalized patients during New York City’s third wave of COVID-19 to the first two waves.

Airway Pressure Release Ventilation in Acute Respiratory Failure Due to COVID-19: When One Door Closes

From Critical Care Medicine In this Letter to the Editor the authors write in reponse to Ibarra-Estrada et al. 

Letters to the Editor: The authors reply to Etiopathogenetic Particularities and Prognostic Impact of Right Ventricular Involvement in COVID-19–Related Acute Respiratory Distress Syndrome

From Critical Care Medicine In this Letter to the Editor the authors respond to Dandel et al.